Drug Discovery Opinion

Alzheimer’s disease is characterised by the presence of neurofibrillary tangles and deposits of amyloid peptides (Aβ) in the brain. N-terminally truncated and pyroglutamate-modified Aβ peptides (Aβ_(pE)) are resistant to proteolysis, aggregate more readily than the unmodified peptides, and have been implicated in the initiation of events leading to the development of Alzheimer’s disease. In post mortem examinations, brains from Alzheimer’s patients were found to contain significantly larger amounts of pyroglutamate-modified peptides than brains from aged controls. Aβ_3(pE)-42, particularly, is a major component of Aβ deposits in both familial and sporadic Alzheimer’s disease.

A recent letter to the journal Nature identifies glutaminyl cyclase as the enzyme which catalyses the N-terminal pyroglutamate formation in vivo. Glutaminyl cyclise protein and mRNA were found to be up-regulated in Alzheimer’s disease patients and significantly larger concentrations of Aβ_3(pE)-42 were also detected. In HEK cells co-expressing amyloid precursor protein (APP) and glutaminyl cyclise, formation of Aβ_3(pE)-42 was suppressed by the glutaminyl cyclase inhibitor, PBD150. Different studies looking at the effect of oral dosing of PBD150 to transgenic mice over 3, 6 or 10 months showed dose-dependent decreases in Aβ_3(pE)-42 and reduced de novo plaque formation. Transgenic mice treated with PBD150 also showed improved memory as determined by a conditioned fear procedure.

The results suggest that formation of Aβ_3(pE)-42 can be reduced by inhibition of glutaminyl cyclise without any effect on previously formed deposits and provide evidence that Aβ_3(pE)-42 can act as a seed for aggregation. If inhibition of glutaminyl cyclise is similarly effective in humans, this could provide a new approach to disease-modifying treatment for Alzheimer’s disease.

Bookmark It

Hide Sites

Related posts:

1. IL-6 Stimulates Amyloid Plaque Clearance Amyloid plaques, which deposit around nerve cells, and neurofibrillary tangles, which build up inside the cells, are the primary hallmarks...
2. PAI-1 inhibitors Help to Clear Amyloid Peptides Amyloid peptide oligomers are believed to contribute to the pathology of Alzheimer’s Disease and much effort has gone into developing...
3. Novel Mechanism of γ-Secretase Modulation It is widely believed that reducing amyloid plaque formation will provide a disease-modifying treatment for Alzheimer’s Disease, either halting or...
4. New Role for APP in Alzheimer’s Disease Cleavage of amyloid precursor protein (APP) by β- and γ-secretases into neurotoxic β-amyloid peptides is believed to play a leading...
5. Challenging the Role of PI3 Kinase in Alzheimer’s Conventional wisdom, supported by in vitro experiments, has previously suggested that phosphoinositide 3-kinase (PI3K) plays a protective role in Alzheimer’s...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Friday, October 17th, 2008 at 8:49 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.